US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Latest lecanemab data to be presented at the AD/PD™ congress

Stockholm, March 5, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company and its collaboration partner Eisai will both present data relating to its investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401), at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD™ 2021.The International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders – which due to the ongoing COVID-19 pandemic will be held online – is a key scientific event with a focus

Alzheimer patients at Swedish clinics to be included in Phase 3 study of drug candidate BAN2401

Stockholm, March 3, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company’s partner Eisai will include Swedish clinics in the confirmatory Phase 3 study of the drug candidate BAN2401. The enrollment of patients with early Alzheimer’s disease will be carried out at memory clinics at four Swedish university hospitals. The global study was initiated in spring 2019 and, according to Eisai, results from the study are expected in 2022. BAN2401 is an antibody that helps the body to eliminate accumulations of misfolded amyloid beta protein. BAN2401 attacks

BioArctic announces research collaboration with Eisai regarding BAN2401

Stockholm, Sweden, December 17, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the initiation of a research collaboration with Eisai aimed at further studying the unique profile of the investigational drug candidate BAN2401. The research collaboration with Eisai is in addition to the existing development and commercialization agreement for BAN2401. This new research collaboration is intended to further characterize the unique binding profile of BAN2401. “We welcome the opportunity to join forces with Eisai in this initiative to generate additional knowledge

BioArctic and Eisai present new data regarding BAN2401 at the Alzheimer’s Association International Conference 2019

Stockholm, Sweden, July 18, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that new data related to BAN2401 were presented on July 17. The presentations were held by BioArctic and its partner, Eisai, at the Alzheimer’s Association International Conference® 2019 (AAIC®) in Los Angeles, USA. BAN2401 was designed and generated to selectively target toxic protofibrils and oligomers, soluble aggregated forms of amyloid beta. The new data included details of the binding profile of BAN2401 and additional analyses from the earlier presented Phase 2b study in 856 patients with early

BioArctic and Eisai to present BAN2401 at the Alzheimer's Association International Conference 2019

Stockholm, Sweden, July 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the Alzheimer’s Association International Conference® 2019 (AAIC®) to be held July 14-18 in Los Angeles, USA. In addition to the presentations, BioArctic’s partner Eisai will sponsor an interactive satellite symposium focusing on the rationale and opportunities for drug development in preclinical Alzheimer’s disease – clinically normal people with increased cerebral amyloid deposition who are at risk for developing Alzheimer’s disease.

BioArctic receives MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s Disease

Stockholm, Sweden, May 20, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR 15 from its partner Eisai for the achievement of the first patient being dosed in the global, single confirmatory Phase 3 study (Clarity AD) with BAN2401 in early Alzheimer´s disease. Eisai is responsible for the clinical development of BAN2401, including this confirmatory Phase 3 study, and BioArctic is entitled to milestone payments and royalties. The total value of the payments to BioArctic under the collaborations can amount to

BioArctic: Alzheimer’s Clinical Trials Consortium and Eisai announce BAN2401 to be evaluated in clinical study for prevention of Alzheimer’s disease

Stockholm, Sweden, May 10, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informed today that the Alzheimer’s Clinical Trials Consortium (ACTC) and BioArctic’s partner Eisai have announced the selection of BAN2401 to be evaluated in an upcoming clinical study targeting secondary prevention of Alzheimer’s disease (the A45 study). This study will be conducted with funding from various sources including the United States National Institute on Aging (NIA), part of the National Institutes of Health (NIH), and Eisai. The ACTC, which is an NIA-funded clinical trial network with 35

BioArctic: Eisai announces timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer’s disease

Stockholm, Sweden, March 7, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informs that Eisai today announced the timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer´s disease patients i.e. mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease. The confirmatory Phase 3 study in early Alzheimer´s disease patients will according to Eisai be initiated in March 2019 and the final readout of primary endpoint is targeted for 2022. The previously announced open-label extension study for patients priorly enrolled in the Phase

BioArctic: Eisai to present additional data from BAN2401 Phase 2b study in early Alzheimer’s disease and the presentation will be webcast live from CTAD

Stockholm, Sweden, October 18, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai will present additional data on the anti-amyloid (Aβ) protofibril antibody BAN2401 clinical Phase 2b study at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference, October 24-27, 2018 in Barcelona, Spain. The presentation will be given during the symposium “Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD” where additional data will be highlighted from the BAN2401 Phase 2b study (ClinicalTrials.gov identifier: NCT01767311). Presentation of

BioArctic obtains exclusive rights to develop antibody treatments for Alzheimer’s disease from a research project jointly owned with Eisai

Stockholm, Sweden, August 7, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has in collaboration with Eisai identified a completely new biological target, which provides an opportunity to develop novel treatments for Alzheimer’s disease. Today BioArctic announced that the company will have exclusive rights to utilize the results from the collaboration to develop potential antibody treatments of Alzheimer’s disease. In 2015 BioArctic and Eisai entered into an equally owned collaboration to investigate new biological targets linked to Alzheimer’s disease. During this research

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media